Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture~* Have a body mass index between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg (110 pounds \[lbs\]) and no more than 100 kg (220 lbs).~* Provision of signed and dated, written informed consent prior to any study specific procedures~Exclusion Criteria:~* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study~* History of haemophilia, von Willebrand's disease, lupus anticoagulant or other diseases/syndromes that can either alter or increase the propensity for bleeding~* A personal history of vascular abnormalities including aneurysms; a personal history of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 3 months prior to the screeening visit; or history suggestive of peptic ulcer disease~* History of frequent and/or significant nose bleed or clinically significant non traumatic bleed, bruise/haematoma or any other clinically significant bleeding risk, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Ticagrelor 90 mg as a whole tablet
- B (Type: EXPERIMENTAL): Ticagrelor 90 mg tablet crushed and suspended in water
- C (Type: EXPERIMENTAL): Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach

Based on this trial design, predict the completion outcome and termination type (if applicable).